INmune Bio Inc. (INMB) Financials

INmune Bio Inc. (INMB) reported diluted earnings per share of -$1.86 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

INmune Bio Inc. (INMB) had EBITDA of -$47.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

INmune Bio Inc. (INMB) has a return on equity of -195.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

INmune Bio Inc. (INMB) recorded an outflow of $23.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

INmune Bio Inc. (INMB) recorded an outflow of $22.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

INmune Bio Inc. (INMB) had $32.4M in total assets as of fiscal year 2025, including both current and long-term assets.

INmune Bio Inc. (INMB) invested $1.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

INmune Bio Inc. (INMB) invested $20.7M in research and development during fiscal year 2025.

INmune Bio Inc. (INMB) had 27M shares outstanding as of fiscal year 2025.

INmune Bio Inc. (INMB) had a current ratio of 3.55 as of fiscal year 2025, which is generally considered healthy.

INmune Bio Inc. (INMB) had a liabilities-to-equity ratio of 0.38 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

INmune Bio Inc. (INMB) had a return on assets of -142.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

INmune Bio Inc. (INMB) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $40.5M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

INmune Bio Inc. (INMB) trades at 810x sales, its market capitalization divided by $50K revenue, FY2025. The market capitalization is $40.5M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, INmune Bio Inc. (INMB) held $24.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.6M over that year. Dividing the one by the other, the reported balance equals about 13 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

INmune Bio Inc. (INMB) has an Altman Z-Score of -10.33, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

INmune Bio Inc. (INMB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

INmune Bio Inc. (INMB) reported a net loss of $45.9M while operations used $22.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.